|
|
|
LifeScienceHistory.com - Check us out on Instagram
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Cellectis, Inc
| | | Phone: | (347) 809-5980 | Year Established: | 1999 | Ticker: | CLLS | Exchange: | NASDAQ | Main Contact: | André Choulika, Ph.D., Chairman & CEO | | Other Contacts: | Stéphane Depil, Senior VP, R&D & CMO Elsy Boglioli, Executive VP, & COO Stefan Scherer M.D., Ph.D., Senior VP, Clinical Development & Deputy CMO
| | Company Description | Cellectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 16 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets. Cellectis S.A. is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). | |
|
|
|
|
|